Mirum Pharmaceuticals, Inc. Common Stock
$96.75
-$1.47 (-1.50%)
$96.54Day Range$100.00
Key Statistics
Market Cap
$6.38B
Shares Outstanding
64.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 18, 2019
Round Lot
100
Locale
US
Trading Data
Day Open
$98.37
Day High
$100.00
Day Low
$96.54
Volume
488.5K
VWAP
$97.87
Prev Close
$98.22
Transactions
--
Acc. Volume
--
About Mirum Pharmaceuticals, Inc. Common Stock
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
PHARMACEUTICAL PREPARATIONSSIC 2834433 employees989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY, CA, 94404650-667-4085IPO Jul 18, 2019US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001759425
- Composite FIGI
- BBG00MH7T2M7
- Share Class FIGI
- BBG00MH7T2N6
- Ticker Root
- MIRM
- SIC Code
- 2834
About Mirum Pharmaceuticals, Inc. Common Stock (MIRM) Stock
Mirum Pharmaceuticals, Inc. Common Stock (MIRM) closed the 2026-09-14 session at $96.75, down 1.50% versus the previous close (-1.47). The stock opened at $98.37 and traded between $96.54 and $100.00 during that session. Session trading volume was 489K shares. The volume-weighted average price (VWAP) is $97.87.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Mirum Pharmaceuticals, Inc. Common Stock has a market capitalization of $6.38 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. MIRM is listed on the XNAS exchange. The company employs approximately 433 people. Mirum Pharmaceuticals, Inc. Common Stock is headquartered in FOSTER CITY, CA. The recorded listing date is 2019-07-18.
On this page you can find market MIRM stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.